Biotech Values

[gym gravity]

Only this:

MLV & Co. analyst George Zavoico said the company is making "good progress" and the delay happened because Prana found some inconsistencies and transcription errors between its database and reports in the study. He said those types of errors are not unusual even though Prana found more of them than it expected. Zavoico said he expect the study to succeed and maintained a "Buy" rating with a price target of $6 per share.